eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2007
vol. 24
 
Share:
Share:
abstract:

Finasteride in androgenetic alopecia in men

Hanna Walkowiak

Post Dermatol Alergol 2007; XXIV, 3: 133–139
Online publish date: 2007/06/22
View full text Get citation
 
Androgenetic alopecia in men occurs in the majority of men over 40 years old and is becoming a significant psychological problem. Androgens have profound effects on scalp and body hair in the human scalp. Testosterone acts in tissues after conversion into dihydrotestosterone. Miniaturization of the scalp hair follicles due to the androgens’ activity constitutes the process background. The alpha 5 reductase enzyme, a key mediator of male pattern loss participating in testosterone metabolism, plays a significant role in the disease aetiopathogenesis. Diagnosis of andogenetic alopecia was based on an interview and the clinical picture. The clinical picture is quite typical and consists of hair loss in the fronto-parietal area. The 8-step Hamilton-Norwood scale is used to evaluate the severity of the disease. The treatment of androgenetic alopecia is not always successful, but has psychological importance. Finasteride is one of the drugs inhibiting androgenetic alopecia in men. The best effects are seen when finasteride is administrated at a dose of 1 mg/day for 24 months. The drug is usually well tolerated and if any adverse events occur, in most cases they are not a reason to interrupt the treatment.
keywords:

androgenetic alopecia in men, alpha 5 reductase enzyme, finasteride

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.